1. Vaccinating America
- Author:
- Committee for Economic Development of the Conference Board
- Publication Date:
- 04-2021
- Content Type:
- Policy Brief
- Institution:
- The Conference Board
- Abstract:
- In December 2020, one year after the COVID-19 virus had been reported in China, the Food and Drug Administration (FDA) granted emergency use authorization in back-to-back announcements for the Pfizer/BioNTech and Moderna/NIAID vaccines. This was by far the fastest vaccine development in history. A typical vaccine took 10 years to develop, with the most rapid previous development being the four years it had taken for the mumps vaccine in 1967.1 And these two vaccines were of a new type, utilizing messenger RNA (mRNA). While mRNA had been studied for years, the unique spike protein of the coronavirus that causes COVID-19 provided a first opportunity to respond with an mRNA vaccine.2 The ensuing technological and scientific success could not have been accomplished without the collaboration of the private and public sectors. The distribution of the vaccine nationally could not have been accomplished without the major delivery companies stepping up to meet the challenges of on-time distribution of the vaccines, which required very cold storage. The research, development, and nationwide distribution of the vaccines has evoked comparisons to the private-public sector collaboration during WWII that led to the Manhattan Project’s rapid and dramatic scientific breakthroughs.3 After death tolls climbed into the hundreds of thousands, the vaccine announcements provided hope that there may be light at the end of the very dark COVID-19 tunnel. By the end of May, the United States is expected to have sufficient vaccine supply for the entire adult American population. But the challenge to manufacture, distribute, and administer the vaccinations quickly, efficiently, and fairly, in a race against continued infection and the emergence of variants of the virus here and all around the world, requires continued collaboration between the public and private sectors. The US and the world must win that race between vaccination and mutation to achieve “herd immunity” and return to normality in daily life and the economy. The stakes are high for both the current crisis and the inevitable pandemics of the future. For this reason, the following analysis offers a diagnosis of the current episode, and recommendations for today and tomorrow.
- Topic:
- Public Health, Vaccine, and COVID-19
- Political Geography:
- North America and United States of America